CSF and blood biomarkers for Parkinson's disease

Lucilla Parnetti, Lorenzo Gaetani, Paolo Eusebi, Silvia Paciotti, Oskar Hansson, Omar Ali El-Agnaf, Brit Mollenhauer, Kaj Blennow, Paolo Calabresi

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.

Original languageEnglish
Pages (from-to)573-586
Number of pages14
JournalThe Lancet Neurology
Volume18
Issue number6
DOIs
Publication statusPublished - 1 Jun 2019

Fingerprint

Synucleins
Parkinson Disease
Biomarkers
Intermediate Filaments
Parkinsonian Disorders
Early Diagnosis
Light
Therapeutic Uses
Amyloid
Differential Diagnosis
Pathology
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., Ali El-Agnaf, O., ... Calabresi, P. (2019). CSF and blood biomarkers for Parkinson's disease. The Lancet Neurology, 18(6), 573-586. https://doi.org/10.1016/S1474-4422(19)30024-9

CSF and blood biomarkers for Parkinson's disease. / Parnetti, Lucilla; Gaetani, Lorenzo; Eusebi, Paolo; Paciotti, Silvia; Hansson, Oskar; Ali El-Agnaf, Omar; Mollenhauer, Brit; Blennow, Kaj; Calabresi, Paolo.

In: The Lancet Neurology, Vol. 18, No. 6, 01.06.2019, p. 573-586.

Research output: Contribution to journalReview article

Parnetti, L, Gaetani, L, Eusebi, P, Paciotti, S, Hansson, O, Ali El-Agnaf, O, Mollenhauer, B, Blennow, K & Calabresi, P 2019, 'CSF and blood biomarkers for Parkinson's disease', The Lancet Neurology, vol. 18, no. 6, pp. 573-586. https://doi.org/10.1016/S1474-4422(19)30024-9
Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, Ali El-Agnaf O et al. CSF and blood biomarkers for Parkinson's disease. The Lancet Neurology. 2019 Jun 1;18(6):573-586. https://doi.org/10.1016/S1474-4422(19)30024-9
Parnetti, Lucilla ; Gaetani, Lorenzo ; Eusebi, Paolo ; Paciotti, Silvia ; Hansson, Oskar ; Ali El-Agnaf, Omar ; Mollenhauer, Brit ; Blennow, Kaj ; Calabresi, Paolo. / CSF and blood biomarkers for Parkinson's disease. In: The Lancet Neurology. 2019 ; Vol. 18, No. 6. pp. 573-586.
@article{290456b80db2450687b4f1aef05ddaf0,
title = "CSF and blood biomarkers for Parkinson's disease",
abstract = "In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.",
author = "Lucilla Parnetti and Lorenzo Gaetani and Paolo Eusebi and Silvia Paciotti and Oskar Hansson and {Ali El-Agnaf}, Omar and Brit Mollenhauer and Kaj Blennow and Paolo Calabresi",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/S1474-4422(19)30024-9",
language = "English",
volume = "18",
pages = "573--586",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "6",

}

TY - JOUR

T1 - CSF and blood biomarkers for Parkinson's disease

AU - Parnetti, Lucilla

AU - Gaetani, Lorenzo

AU - Eusebi, Paolo

AU - Paciotti, Silvia

AU - Hansson, Oskar

AU - Ali El-Agnaf, Omar

AU - Mollenhauer, Brit

AU - Blennow, Kaj

AU - Calabresi, Paolo

PY - 2019/6/1

Y1 - 2019/6/1

N2 - In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.

AB - In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical symptoms, which hampers the detection of the earliest phases of the disease—the time at which treatment with forthcoming disease-modifying drugs could have the greatest therapeutic effect. Reliable prognostic markers could help in predicting the response to treatments. Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain. A combination of multiple CSF biomarkers has emerged as an accurate diagnostic and prognostic model. With respect to early diagnosis, the measurement of CSF α-synuclein aggregates is providing encouraging preliminary results. Blood α-synuclein species and neurofilament light chain are also under investigation because they would provide a non-invasive tool, both for early and differential diagnosis of Parkinson's disease versus atypical parkinsonian disorders, and for disease monitoring. In view of adopting CSF and blood biomarkers for improving Parkinson's disease diagnostic and prognostic accuracy, further validation in large independent cohorts is needed.

UR - http://www.scopus.com/inward/record.url?scp=85065771657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065771657&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(19)30024-9

DO - 10.1016/S1474-4422(19)30024-9

M3 - Review article

C2 - 30981640

AN - SCOPUS:85065771657

VL - 18

SP - 573

EP - 586

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 6

ER -